DHDH: Potential Drug Target Or Biomarker (G27294)

Target Name: DHDH

NCBI ID: G27294

DHDH

DHDH: Potential Drug Target Or Biomarker

D-xylose:NADP+ oxidoreductase (DHDH) is a enzyme that plays a crucial role in the metabolism of xylose, a simple sugar found in a wide variety of fruits and vegetables. In the human body, xylose is primarily used as a source of energy by the body's cells. However, when xylose is consumed in excess, it can lead to a variety of negative health effects, including obesity, type 2 diabetes, and cardiovascular disease.

DHDH is an enzyme that is expressed in high levels in the liver and other tissues throughout the body. It is responsible for the metabolism of xylose to xylose 6-phosphate, which is then converted into glucose. DHDH is a key enzyme in the xylose metabolism, and its function is critical for maintaining the body's energy balance.

Recent studies have suggested that DHDH may have potential as a drug target or biomarker for a variety of diseases. One potential mechanism by which DHDH may be involved in the development of obesity is by regulating the body's sensitivity to insulin. Insulin is a hormone that helps to regulate blood sugar levels, and it is known to play a key role in the development of obesity.

Several studies have shown that individuals with certain genetic variations in the DHDH gene are more likely to be overweight or obese. These genetic variations have been associated with alterations in the body's metabolism of xylose, leading to an increased risk of obesity.

Another potential mechanism by which DHDH may be involved in the development of type 2 diabetes is by modulating the body's sensitivity to insulin. Type 2 diabetes is a disease in which the body's cells are less responsive to insulin, leading to high levels of blood sugar. DHDH has been shown to play a role in the regulation of insulin sensitivity, and studies have suggested that alterations in DHDH activity may contribute to the development of type 2 diabetes.

In addition to its potential role in the development of obesity and type 2 diabetes, DHDH has also been shown to be involved in a variety of other biological processes. For example, DHDH has been shown to play a key role in the regulation of cell death, and alterations in DHDH activity have been linked to a variety of diseases, including cancer.

Despite the potential for DHDH to be a drug target or biomarker, further research is needed to fully understand its role in the body. Currently, there are no FDA-approved drugs that target DHDH specifically. Researchers are also in the process of studying the potential benefits and risks of using DHDH as a drug or biomarker, and more studies are needed to determine the safety and effectiveness of this approach.

In conclusion, D-xylose:NADP+ oxidoreductase (DHDH) is a crucial enzyme that plays a critical role in the metabolism of xylose in the human body. Recent studies have suggested that DHDH may have potential as a drug target or biomarker for a variety of diseases, including obesity and type 2 diabetes. Further research is needed to fully understand the role of DHDH in the body and its potential as a drug or biomarker.

Protein Name: Dihydrodiol Dehydrogenase

The "DHDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets